-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $150

Benzinga·05/14/2026 14:17:47
Listen to the news
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $170 to $150.